Association of Systemic Vascular Resistance Analog and Cardiovascular Outcomes: The Heart and Soul Study

Dai-Yin Lu1,2, Qizhi Fang1, Dwight Bibby1

  • 1Division of Cardiology University of California San Francisco CA.

Insights

An elevated estimated systemic vascular resistance (eSVR) is linked to increased cardiovascular events in patients with coronary artery disease. Persistently high eSVR indicates a higher risk of adverse outcomes.

Area of Science:

  • Cardiology
  • Hemodynamics
  • Echocardiography

Background:

  • Systemic vascular resistance (SVR) is a key hemodynamic parameter.
  • Estimated SVR (eSVR) derived from echocardiography correlates with direct SVR measurements.
  • The prognostic value of eSVR has not been established.

Purpose of the Study:

  • To investigate the prognostic impact of baseline and follow-up eSVR on cardiovascular outcomes in patients with coronary artery disease.
  • To determine if eSVR is a better predictor of cardiovascular events than systolic blood pressure alone.

Main Methods:

  • Utilized data from 984 participants with established coronary artery disease in the Heart and Soul Study.
  • Defined Doppler-derived eSVR as the ratio of systolic blood pressure to left ventricular outflow tract velocity time integral.
  • Categorized participants into baseline eSVR tertiles and assessed cardiovascular outcomes, including heart failure, major cardiovascular events, and all-cause death, with follow-up eSVR calculated at year five.

Main Results:

  • Higher baseline eSVR tertiles were associated with older age, higher systolic blood pressure, and lower left ventricular outflow tract velocity time integral.
  • An elevated eSVR was significantly associated with increased risks of heart failure, major cardiovascular events (HR 1.38, 95% CI 1.02-1.86), and death.
  • Persistently elevated eSVR during follow-up correlated with the most adverse cardiovascular outcomes.

Conclusions:

  • Elevated eSVR, calculated from systolic blood pressure and left ventricular outflow tract velocity time integral, demonstrates a stronger correlation with cardiovascular events than systolic blood pressure alone.
  • Repeatedly elevated eSVR is a significant predictor of adverse cardiovascular outcomes in patients with coronary artery disease.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
493
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
3.1K
Vascular Resistance01:20

Vascular Resistance

Vascular resistance is a critical concept in understanding blood flow dynamics in the circulatory system. It refers to the resistance that blood encounters as it flows through the blood vessels. This resistance is a key factor in determining blood pressure and cardiac workload.
The primary determinants of vascular resistance are vessel diameter, blood viscosity, and vessel length. Among these, vessel diameter plays the most significant role due to the fourth power relationship described by...
5.0K
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
625
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
221
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
248